Content area
Full text
Dennis Gillings has built Quintiles into one of the world's largest contract research organizations. Gillings took Quintiles public in 1994, and the Durham-based company in 1998 became the first in its field to top $1 billion in net revenue. Gillings diversified Quintiles into investing in drug companies and even some drug development of his own. He gave up the CEO title in 2002, but then launched a successful bid to buy back the company in 2003. Teaming with One Equity Partners LLC, Gillings reacquired the company for $1.7 billion and took it private.